Thinle Chodon
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Molecular Biology top 2%
- Melanoma and MAPK Pathways
Papers in
- Immunology 19
- Immunotherapy and Immune Responses 18
- T-cell and B-cell Immunology 6
- Immune cells in cancer 1
- Oncology 20
- Cancer Immunotherapy and Biomarkers 10
- CAR-T cell therapy research 8
- Co-authors
- Antoni Ribas (21 shared papers)Richard Chikara Koya (24 shared papers)Hubing Shi (4 shared papers)Xiangju Kong (4 shared papers)Roger S. Lo (4 shared papers)Jeffrey Alan Sosman (3 shared papers)Begoña Comı́n-Anduix (16 shared papers)Mi‐Kyung Lee (2 shared papers)
- Journals
- Clinical Cancer Research (5 papers)Journal for ImmunoTherapy of Cancer (4 papers)Journal of Immunotherapy (4 papers)Cancer Discovery (3 papers)Transplantation and Cellular Therapy (2 papers)
- Partner nations
- United StatesAustraliaJapan
In The Last Decade
Thinle Chodon
38 papers receiving 6.2k citations
Thinle Chodon's Hit Papers
Peers
Comparison fields: 5 of 95
- Oncology 2.2k
- Molecular Biology 3k
- Immunology 683
- Cancer Research 398
- Dermatology 165
Countries citing papers authored by Thinle Chodon
This map shows the geographic impact of Thinle Chodon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thinle Chodon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thinle Chodon more than expected).
Fields of papers citing papers by Thinle Chodon
This network shows the impact of papers produced by Thinle Chodon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thinle Chodon. The network helps show where Thinle Chodon may publish in the future.
Co-authors
The 25 scholars most cited alongside Thinle Chodon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Hit paper breakdown → | 2010 | 1820 |
| 2 | Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Hit paper breakdown → | 2013 | 828 |
| 3 | 2012 | 540 | |
| 4 | 2011 | 380 | |
| 5 | 2016 | 347 | |
| 6 | 2014 | 315 | |
| 7 | 2014 | 302 | |
| 8 | 2014 | 215 | |
| 9 | 2012 | 204 | |
| 10 | 2009 | 158 | |
| 11 | 2013 | 150 | |
| 12 | 2013 | 125 | |
| 13 | 2010 | 120 | |
| 14 | 2003 | 108 | |
| 15 | 2000 | 104 | |
| 16 | 2019 | 73 | |
| 17 | 2022 | 61 | |
| 18 | 2010 | 54 | |
| 19 | 2021 | 44 | |
| 20 | 2010 | 41 |
About Thinle Chodon
Thinle Chodon is a scholar working on Immunology, Oncology, Molecular Biology, Dermatology and Hematology, having authored 39 papers that have together received 6.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (18 papers), Cancer Immunotherapy and Biomarkers (10 papers), CAR-T cell therapy research (8 papers), Melanoma and MAPK Pathways (7 papers), T-cell and B-cell Immunology (6 papers), Multiple Myeloma Research and Treatments (2 papers), Dermatologic Treatments and Research (2 papers) and Immune cells in cancer (1 paper). The work is most often cited by research in Oncology (2.2k citations), Molecular Biology (3k citations), Immunology (683 citations), Cancer Research (398 citations) and Dermatology (165 citations). Thinle Chodon has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Antoni Ribas, Richard Chikara Koya, Hubing Shi, Xiangju Kong, Roger S. Lo, Jeffrey Alan Sosman, Begoña Comı́n-Anduix, Mi‐Kyung Lee, Stanley F. Nelson and Hane Lee. Their work appears in journals such as Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Journal of Immunotherapy, Cancer Discovery and Transplantation and Cellular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.